Wall Street analysts expect Waters Co. (NYSE:WAT) to post $2.13 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Waters’ earnings, with estimates ranging from $2.11 to $2.15. Waters reported earnings per share of $1.92 in the same quarter last year, which indicates a positive year over year growth rate of 10.9%. The company is scheduled to report its next earnings results on Tuesday, October 22nd.

According to Zacks, analysts expect that Waters will report full year earnings of $9.01 per share for the current year, with EPS estimates ranging from $8.95 to $9.05. For the next financial year, analysts forecast that the company will post earnings of $10.12 per share, with EPS estimates ranging from $9.82 to $10.82. Zacks’ earnings per share calculations are an average based on a survey of analysts that follow Waters.

Waters (NYSE:WAT) last posted its quarterly earnings results on Tuesday, July 30th. The medical instruments supplier reported $2.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.11 by $0.03. Waters had a return on equity of 50.64% and a net margin of 24.09%. The business had revenue of $599.20 million during the quarter, compared to analyst estimates of $601.46 million. During the same period in the prior year, the business earned $1.95 earnings per share. The business’s revenue was up .5% compared to the same quarter last year.

WAT has been the subject of several analyst reports. Bank of America cut Waters from a “neutral” rating to an “underperform” rating in a report on Tuesday, July 16th. ValuEngine lowered Waters from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Wolfe Research started coverage on shares of Waters in a research report on Thursday, May 30th. They set an “underperform” rating on the stock. Zacks Investment Research raised shares of Waters from a “sell” rating to a “hold” rating and set a $217.00 price target on the stock in a research report on Wednesday, May 22nd. Finally, Cleveland Research lowered shares of Waters from a “neutral” rating to an “underperform” rating in a report on Wednesday, June 12th. Five investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $210.54.

Waters stock traded up $8.07 during trading on Wednesday, reaching $231.26. 844,900 shares of the company were exchanged, compared to its average volume of 603,671. The stock’s 50 day simple moving average is $211.39 and its two-hundred day simple moving average is $221.34. The company has a market capitalization of $14.49 billion, a P/E ratio of 27.90, a PEG ratio of 2.43 and a beta of 1.08. The company has a debt-to-equity ratio of 2.00, a current ratio of 2.65 and a quick ratio of 2.07. Waters has a 52-week low of $167.93 and a 52-week high of $255.21.

Hedge funds have recently bought and sold shares of the business. Compagnie Lombard Odier SCmA acquired a new position in shares of Waters in the 2nd quarter valued at $37,000. CSat Investment Advisory L.P. increased its position in shares of Waters by 212.5% during the 2nd quarter. CSat Investment Advisory L.P. now owns 225 shares of the medical instruments supplier’s stock worth $48,000 after purchasing an additional 153 shares during the last quarter. Private Capital Group LLC increased its position in shares of Waters by 92.0% during the 2nd quarter. Private Capital Group LLC now owns 288 shares of the medical instruments supplier’s stock worth $56,000 after purchasing an additional 138 shares during the last quarter. Thor Advisors LLC acquired a new stake in shares of Waters during the 1st quarter worth about $64,000. Finally, Amica Retiree Medical Trust purchased a new stake in Waters in the 2nd quarter valued at about $69,000. 95.08% of the stock is owned by institutional investors.

About Waters

Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.

See Also: Dead Cat Bounce

Get a free copy of the Zacks research report on Waters (WAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Waters (NYSE:WAT)

Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.